TimothyJPluardMD

Breast Cancer

Koontz Endowed Chair in Breast Disease, University of Missouri, Kansas City School of Medicine. Director Saint Luke's Cancer Institute

Join to view full profile

Dr. Pluard is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pluard's full profile

Already have an account?

Office
4401 Wornall Rd
Kansas City, MO 64111
Phone+1 816-932-3800

Fax+1 816-932-3888

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1991 - 1993
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1987 - 1991
Washington University in St. Louis School of MedicineClass of 1987

Certifications & Licensure

MO State Medical License 1993 - 2025
KS State Medical License 2014 - 2024
FL State Medical License 2020 - 2022
TX State Medical License 1988 - 1992
American Board of Internal Medicine Medical Oncology

Clinical Trials

Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer Start of enrollment: 2011 Sep 01
Terminated
Phase 2
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
Completed
Phase 2
Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer Start of enrollment: 2013 Jan 10
Terminated
Phase 3
Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03
Terminated
Phase 1, Phase 2
Axillary Ultrasound With or Without Sentinel Lymph Node Biopsy in Detecting the Spread of Breast Cancer in Patients Receiving Breast Conservation Therapy Start of enrollment: 2013 Apr 04
Terminated
Not Applicable
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Terminated
Phase 2
Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer Start of enrollment: 2018 Jul 06
Completed
Phase 2
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer Start of enrollment: 2022 Mar 07
Recruiting
Phase 3
Roles: Contact, Principal Investigator
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Start of enrollment: 2023 Oct 31
Recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

225 citations
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial
Rebecca Aft, Michael Naughton, Kathryn Trinkaus, Mark A. Watson, Lourdes R. Ylagan
The Lancet. Oncology. 2010-05-01
195 citations
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
Linda M Liau, Keyoumars Ashkan, David D Tran, Jian L Campian, John E Trusheim
Journal of Translational Medicine. 2018-05-29
472 citations
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.
Shunqiang Li, Dong Shen, Jieya Shao, Robert J. Crowder, Wenbin Liu
Cell Reports. 2013-09-26

Lectures

The Utility of Hereditary Thrombophilia Testing Among Hospitalized Patients: A Single Center Experience
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Highlights of the 2011 San Antonio Breast Cancer Symposium
Washington University School of Medicine, Saint Louis, Missouri - 2/11/2012

Press Mentions

The Power of Metastatic Breast Cancer Retreats with Lillie Shockney and Janie Metsker: Part 1October 28th, 2022
Saint Luke's Cancer Institute & Patient Discovery Launches Innovative Digital Advocate for Advance Care PlanningJune 10th, 2021
Anova Announces Formation of Scientific Advisory Board to Advance Development of Its Technology Platform Transforming Clinical DevelopmentOctober 7th, 2020
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member